JPS61233622A - Eye lotion composition - Google Patents
Eye lotion compositionInfo
- Publication number
- JPS61233622A JPS61233622A JP7515285A JP7515285A JPS61233622A JP S61233622 A JPS61233622 A JP S61233622A JP 7515285 A JP7515285 A JP 7515285A JP 7515285 A JP7515285 A JP 7515285A JP S61233622 A JPS61233622 A JP S61233622A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- salts
- eye
- mucopolysaccharide
- histidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は新規な眼薬組成物、更に詳しくは酸性ムコ多糖
類、アスコルビン酸またはそれらの塩類の１種または２
種以上とトリプトファン、じスチレン、尿酸またはそれ
らの塩類の１種または２種以上を併用してなる眼薬組成
物に関する。Detailed Description of the Invention [Industrial Application Field] The present invention provides a novel ophthalmic composition, more specifically, a novel ophthalmic composition containing one or two of acidic mucopolysaccharides, ascorbic acid, or salts thereof.
The present invention relates to an eye drug composition containing one or more of tryptophan, distyrene, uric acid, or salts thereof.
［従来の技術およびその問題点］
哺乳動物の眼水晶体にはヒアルロン酸をはじめとしコン
ドロイチン硫酸、コンドロイチンなどの酸性ムニ］多糖
類が存在し水晶体の形状保持および透明ガラス体形成等
の役割を担っているが、これ等酸性ムコ多糖類とともに
アスコルビン酸もバ存してることが知られている。また
、最近の研究では老人性眼疾患がこね等酸性ムコ多糖類
の化学的変化によると考えられ老化現象の関係が深いこ
とを示しているが、現在その予防方法はほとんどない。[Prior art and its problems] The mammalian eye lens contains acidic polysaccharides such as hyaluronic acid, chondroitin sulfate, and chondroitin, which play a role in maintaining the shape of the lens and forming a transparent vitreous body. However, it is known that ascorbic acid is present along with these acidic mucopolysaccharides. In addition, recent research has shown that senile eye diseases are thought to be caused by chemical changes in acidic mucopolysaccharides, and are closely related to aging phenomena, but there are currently few methods for preventing them.
ざらに ｉｎ ＶｉｔｒＯ研究ではあるが鉄・銅のよう
な生体組織に存在する金属イオンにより酸性ムコ多糖類
の著しい低分子化が確認され（ＦＦＢＳＬＥＴＴＥＲ８
９６，２，２３８，１９７８）さらにアスコルビン酸の
添加により低分子化が促進される（ＪＯＩＩｒｎａｌ
ｏｆ ｌ ｎ０ｒｊｌａｎｔｃ Ｂ！０ＣＩＩＱＩＩ
Ｉ−ｉｓｔｒｙ上４，１３５ （１９８１）ことが確認
されている。しかし、正常水晶体においては酸性ムコ多
糖とアスコルビン酸が共存し当然金属イオンも含有する
と思われるが非常に安定に保たれている。Although this is an in-VitrO study, it has been confirmed that acidic mucopolysaccharides are significantly reduced in molecular weight by metal ions such as iron and copper present in living tissues (FFBSLETTER8).
96, 2, 238, 1978) Furthermore, the addition of ascorbic acid promotes the reduction of molecular weight (JOIIrnal
of l n0rjlantc B! 0CIIQII
I-istry 4, 135 (1981). However, in a normal crystalline lens, acidic mucopolysaccharide and ascorbic acid coexist, and although it is thought that metal ions are also contained, it is kept very stable.
すなわち、第三成分の存在が推察される。In other words, the presence of a third component is inferred.
本発明り等は白内障、緑内障イＴどの眼疾患が眼球内に
存在ツノている酸性ムコ多糖うＩ、アスコルビン酸の代
ｉ’ｌｉ巽状に」る点を考え、特に水晶体の１丁成分で
ある酸性ムコ多糖類を安定化し眼病の治療およσ予防に
、さらには眼薬どしＣ使用される酸Ｉ１１ムコ多糖類で
あるヒアルロン酸、］コンドロイチン］ン１〜［］イデ
シン！ＩＭ、デルマタン硫酸、ｌ＼バリン、ヘパラン硫
酸、ツノラウン硫酸など、ｄ−３よひ各）（のｌルカリ
金属塩の酸化的・光的低ヅ）子化を防用１ノ、すｊ力持
続性の良い眼薬組成物を提供じ１１−常／「眼機能キ１
１持を目的どηるものＣ゛ある。The present invention has been developed based on the fact that eye diseases such as cataracts and glaucoma are caused by acidic mucopolysaccharide, which exists in the eyeball, and ascorbic acid, and in particular, it is a component of the crystalline lens. Acid I11 Mucopolysaccharide hyaluronic acid, [chondroitin]1~[]idecine! is used to stabilize certain acidic mucopolysaccharides and to treat eye diseases and prevent σ, and is also used in eye medicines. IM, dermatan sulfate, l\valine, heparan sulfate, tunoraun sulfate, etc., d-3, etc.) Prevents the oxidative and photo-degradation of alkali metal salts and maintains its strength. 11-Continue / "Eye Function Key 1"
There are some people whose purpose is to have one.
［問題点を解決する為の手段］
本ブを明省舌は眼共について検討した結果、アスコルビ
ン酸、全屈イＡンなどの低分子化促進因子の（ｒ＋ｆ−
Ｆ Ｃし、１〜リブ１ヘフアン、ヒスデシン、尿酸また
はでれらの塩類を」（存せしめることにより、酸Ｉ′Ｕ
： ｌｘ ｚｒ多糖類の低分子化が防山できることを見
い出し、本発明を完成した１うのである。[Means for solving the problem] As a result of examining this topic for the eyes, we found that (r+f-
F C, 1~rib 1 hefan, hisdecine, uric acid or their salts (by containing acid I'U)
: It was discovered that reducing the molecular weight of lx zr polysaccharide can be used for mountain prevention, and the present invention was completed.
本発明の眼Ａも組成物ＩＪ耐１リム］多ｉ１Ｊ＋知、デ
ス。ニー１ルピン酸またｌｊニーｆれらの塩類の１種ま
たは２種以上と１−リブトファン、ヒスチジン、ＳＲま
たはそれらの塩類の１種または２種以上をイ）（用Ｊ−
ることから４ｆる。The eye A of the present invention also has a composition IJ resistance 1 rim] polyi1J+knowledge, death. A) One or more of these salts and one or more of 1-ributophane, histidine, SR, or their salts (a) (for J-
4f from that.
本発明でいう酸性ムコ多糖類とはヒアルロン酸、コンド
ロイチン、コンドロイチン硫酸、デルマタン硫酸、ヘパ
リン、ヘパラン硫酸、グラタン硫酸などおよびこれらの
すＩ〜リウム、カリウム、カルシウム、アンモニウム、
アミン、アミノＭｌｉ塩などであり、アスコルビン酸お
よびそのすトリウム、カリウム、カルシウム塩などから
）巽ばれる１種または２種以上０．０１〜５重量％の範
囲で配合する。Acidic mucopolysaccharides as used in the present invention include hyaluronic acid, chondroitin, chondroitin sulfate, dermatan sulfate, heparin, heparan sulfate, gratan sulfate, etc., and these salts, potassium, calcium, ammonium,
Ascorbic acid and its thorium, potassium, calcium salts, etc.) are mixed in an amount of 0.01 to 5% by weight.
０．０１重量％以下では目的どＪる治療、予防効果が得
られず、５重量％以上は効果と経済性から必要ない。If the amount is less than 0.01% by weight, the desired therapeutic or preventive effect cannot be obtained, and if it is more than 5% by weight, it is not necessary from the viewpoint of efficacy and economy.
本発明でいう］ヘリプＩ〜フ７７ン、ヒスチジン、尿酸
またはその塩類とは、トリプトファンまたはその塩類と
してはＤＬ−１〜リプ１〜フアン、１−−１〜リプ］へ
ファン及びこれらの塩酸塩、硝酸塩、酢酸塩、硫酸塩を
さし、じスヂジンすたはその塩類どじではＬ−ヒスチジ
ン及びこれの塩酸塩、硝酸塩、酢ＭＪｉ、硫酸塩をさし
、尿酸またはその塩類どして１ｅｔ１、尿酸、尿酸づ］
・リウム、尿酸カリウム、尿酸カルシウム、尿酸水素±
１−リウム、尿酸水素カリウノ１、尿酸水素カルシ１ク
ム、尿酸水素アンモニウム、尿酸アミノ酸塩、尿酸アミ
ン塩などをいい、添加量１１１０，０１〜１．０重量％
であり、０．０１巾帛％以十（・は目的どする効甲が得
られず、 １．０重量％以−には溶解性と効果の点で必
要ない。In the present invention, tryptophan, histidine, uric acid, or its salts include tryptophan or its salts, including DL-1, 1--1, 1--1, and their hydrochlorides. , refers to nitrate, acetate, sulfate, and its salts include L-histidine and its hydrochloride, nitrate, vinegar MJi, and sulfate, and uric acid or its salts refers to 1et1, uric acid, uric acid]
・Rium, potassium urate, calcium urate, hydrogen urate±
1-lium, potassium hydrogen urate 1, calci hydrogen urate 1 cum, ammonium hydrogen urate, uric acid amino acid salt, uric acid amine salt, etc., added in an amount of 1110.01 to 1.0% by weight.
If the content is 0.01% by weight or more, the desired effect cannot be obtained, and if it is less than 1.0% by weight, it is unnecessary in terms of solubility and effectiveness.
まｋ 、眼薬は浸透１−ｆを調整するため食塩、リン酸
り一１〜リウムなどの無機ｉｎを添加する場合もあるが
本発明組成物には何等影響覆るものではない。In some cases, inorganic inorganic substances such as common salt and monolithium phosphate are added to eye drops in order to adjust the penetration level 1-f, but this does not affect the composition of the present invention in any way.
なお、本発明組成物の１１−１値は４．０〜８．０好ま
し）くけ６．０〜７．Ｏに維持することが望ましい。The 11-1 value of the composition of the present invention is preferably 4.0 to 8.0) and 6.0 to 7. It is desirable to maintain it at 0.
ｐ ｌ−１値４．０以下およびｐｌ−１値８．０以上で
は逆に眼組織の変質による刺激が強く眼薬どしでの用を
足さくｒ ＜ １．７るばかりか眼組織の炎症を誘発１
．でしまう３、
本発明眼薬組成物（，１白内障、緑内障等の水晶体内酸
１１ムコ多糖化学的性質の変化により誘発される１Ｒ病
の治療ｒｌｌ；−は眼疾患の治療さらにはＴ−防子５一
段に使用されるものであるが、角膜移植手術等眼病の外
科手術時の眼組織の保存液または眼組織の形状保持用注
入液にも適用しうる。On the other hand, when the p l-1 value is less than 4.0 and the p l-1 value is more than 8.0, the irritation caused by the deterioration of the eye tissue is strong enough to make it difficult to use eye medicine. induce inflammation 1
．． 3. The ophthalmic composition of the present invention (1) Treatment of 1R disease induced by changes in intralenticular acid 11 mucopolysaccharide chemical properties such as cataracts and glaucoma; Although the present invention is used in the first stage, it can also be applied as an eye tissue preservation solution or an injection solution for maintaining the shape of eye tissue during eye disease surgery such as corneal transplant surgery.
以下本発明服薬組成物について実施例、実験例で説明す
る。The pharmaceutical composition of the present invention will be explained below using Examples and Experimental Examples.
実施例１．白内障防止眼薬
ヒアルロン酸ナトリウｌｘ ０．０５重量％
コンドロイチン硫酸す１ヘリウム ０ 、５Ｏｎトリプ
トファン塩酸塩 ０．０２ 〃塩化すＩ〜
リウム ２． Ｑ ｎ滅菌精製水
９７．４３ 、。Example 1. Cataract prevention eye medicine sodium hyaluronate lx 0.05% by weight
Chondroitin sulfate 1 helium 0, 5 On tryptophan hydrochloride 0.02 Chloride I~
Rium 2. QnSterilized purified water
97.43,.
実施例２．健康美眼剤
塩酸ナファゾリン ０．１ 重量％］コ
ンドロイチン硫酸１ヘリウム ｉ、ｏ 、。Example 2. Healthy eye beauty agent Naphazoline hydrochloride 0.1% by weight] Chondroitin sulfate 1 helium i,o.
尿酸ナトリウム ０．１ 、。Sodium urate 0.1.
サロメチール ０．２〃塩化ナトリ
ウム ２，０ ．１滅菌精製水
９６，６ 、Ｊ実施例３０手術用
角膜乾燥防市剤
ヒアルロン酸ナトリウム ０．３ 重量％塩
化プ１〜リウム ５．ＯＩ！ｊ話化カリ
ウム ２．０！・リン酸水水−ノトリ
ウム ０，１ ｎホウ酸
０．３ ・１１ｐ酎 ツノ リ ウ
１１ ０，０
３ ノＩアス］ルピン酸ブー １−リウム
０．２／Ｉ滅菌精製水 ９２．
１！！実施例４．＝］ンタクトレンズ用点眼剤ヒフ））
し［１ン酸カリウム ０．・２ 重石％１
−−ヒスチジン塩酸塩 ０．１１１アス］ル
ｌ：゛ン酸−ノトリ１クム ０．１１Ｉｌｐ化す
１〜リウム ２，０ ！！滅菌精製
水 ！１１７．６ ！ｌ実験例
１
年齢２３へ・５０才の事務を業とし目の疲れを毎日又は
時々感する人２５人、うち女ｆＩＪ６、男性１９人に実
施例２の１梨を１日３回１〜２滴使用し水剤使用前と使
用後の眼疲労感および充血性を調べ Ｉこ 。Salomethyl 0.2 Sodium chloride 2.0. 1 Sterile purified water
96,6, J Example 30 Surgical corneal drying preventive agent Sodium hyaluronate 0.3% by weight Pr1-Rium chloride 5. OI! J talk potassium 2.0!・Phosphoric acid water - Notorium 0,1 n boric acid
0.3 ・11p Shochu Tsuno Riu
11 0,0
3 NoIas] 1-rium lupine acid
0.2/I sterile purified water 92.
1! ! Example 4. =] Eye drops for contact lenses Hif))
[Potassium monophosphate 0.・2 Weight%1
--Histidine hydrochloride 0.111 As]l: 1 cum of dinic acid 0.11Ilp 1~Rium 2,0! ! Sterile purified water! 117.6! l Experimental Example 1 Age 23 - 25 50-year-olds who work in office work and experience eye strain every day or occasionally, including 6 women and 19 men, were given 1 pear of Example 2 1 to 2 times a day. Eye fatigue and hyperemia were investigated using drops before and after using the solution.
本発明品は眼疲労及び充血に対して著しい効宋を示した
。The product of the present invention showed remarkable effects on eye fatigue and hyperemia.
実験例２
実施例３にて調整した水溶液にラット眼球を摘出後直ち
に浸漬し眼球の鮮度および色調を調べた。Experimental Example 2 Immediately after enucleating rat eyeballs, they were immersed in the aqueous solution prepared in Example 3, and the freshness and color tone of the eyeballs were examined.
なお湿度は５°Ｃにてｐｌ−１６，７に調整して行った
。The humidity was adjusted to pl-16.7 at 5°C.
比較例１とは実施例３よりヒアルロン酸ナトリウム、尿
酸す１ヘリウムを除いた調整液。Comparative Example 1 is a prepared solution obtained by removing sodium hyaluronate, uric acid, and helium from Example 3.
比較例２とは実施例３より尿酸す］〜リウムを除いた調
整液。Comparative Example 2 is a prepared solution obtained by removing uric acid from Example 3.
たたし表中数字は摘出直後のラン１〜眼球にほぼ同じ色
調を保っていた個体数を表わす。The numbers in the table represent the number of individuals whose eyeballs had almost the same color tone from run 1 immediately after extraction.
本発明品は４８時間後でも色調が良好に保てたがヒアル
ロン酸す１〜リウムと尿酸ナトリウムを除いた比較例１
及び尿酸ナトリウムを除いた比較例２は１！い１ｆい８
時間稈度しか保存できなかった。Although the product of the present invention maintained good color tone even after 48 hours, Comparative Example 1 in which mono-lium hyaluronic acid and sodium urate were excluded
And Comparative Example 2 excluding sodium urate was 1! i1f i8
Only time culm could be saved.
Claims (1)
ら選ばれる１種または２種以上０．０１〜５重量％およ
びトリプトファン、ヒスチジン、尿酸またはそれらの塩
類から選ばれる１種または２種以上０．００１〜１重量
％を含有してなる眼薬組成物。0.01 to 5% by weight of one or more selected from acidic mucopolysaccharides, ascorbic acid, or their salts, and 0.001 to 5% by weight of one or more selected from tryptophan, histidine, uric acid, or their salts. An eye drug composition containing 1% by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7515285A JPS61233622A (en) | 1985-04-09 | 1985-04-09 | Eye lotion composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7515285A JPS61233622A (en) | 1985-04-09 | 1985-04-09 | Eye lotion composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61233622A true JPS61233622A (en) | 1986-10-17 |
| JPS6410500B2 JPS6410500B2 (en) | 1989-02-22 |
Family
ID=13567943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7515285A Granted JPS61233622A (en) | 1985-04-09 | 1985-04-09 | Eye lotion composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61233622A (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989000044A1 (en) * | 1987-07-07 | 1989-01-12 | Santen Pharmaceutical Co., Ltd. | Artificial lacrima |
| JPH01294633A (en) * | 1988-05-23 | 1989-11-28 | Fujisawa Pharmaceut Co Ltd | Ophthalmic solution |
| EP0735895A1 (en) * | 1993-11-19 | 1996-10-09 | The University Of Sydney | A method for preventing or controlling cataract |
| US5614506A (en) * | 1991-07-03 | 1997-03-25 | Hyal Pharmaceutical Corporation | Use of hyaluronic acid and forms to prevent arterial restenosis |
| US5811410A (en) * | 1989-09-21 | 1998-09-22 | Hyal Pharmaceutical Corporation | Method of administering of a hyaluronic acid and an NSAID to decrease side effects of the NSAID |
| US5817644A (en) * | 1991-07-03 | 1998-10-06 | Hyal Pharmaceutical Corporation | Targeting of dosages of medicine and therapeutic agents |
| GR970100233A (en) * | 1997-06-09 | 1999-02-26 | Use of organic, anti-oxidant substances for the protection of the lungs, the skin and the eyes from free radicals | |
| US5942498A (en) * | 1992-02-20 | 1999-08-24 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
| US5990095A (en) * | 1991-07-03 | 1999-11-23 | Hyal Pharmaceutical Corporation | Use of hyaluronic acid and forms to prevent arterial restenosis |
| US6022866A (en) * | 1991-07-03 | 2000-02-08 | Hyal Pharmaceutical Corporation | Use of hyaluronic acid and forms to prevent arterial restenosis |
| WO2001006868A1 (en) * | 1999-07-28 | 2001-02-01 | Biomar Group | Feed for salmonids |
| WO2008050776A1 (en) | 2006-10-26 | 2008-05-02 | Senju Pharmaceutical Co., Ltd. | Ophthalmic aqeous liquid preparation |
| JP2010180206A (en) * | 2009-01-09 | 2010-08-19 | Rohto Pharmaceut Co Ltd | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
| JP2011030455A (en) * | 2009-07-30 | 2011-02-17 | Uha Mikakuto Co Ltd | Food material containing tryptophan-hyaluronic acid and food material containing peptide with high tryptophan-content and hyaluronic acid and methods for producing the same |
-
1985
- 1985-04-09 JP JP7515285A patent/JPS61233622A/en active Granted
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989000044A1 (en) * | 1987-07-07 | 1989-01-12 | Santen Pharmaceutical Co., Ltd. | Artificial lacrima |
| JPH01294633A (en) * | 1988-05-23 | 1989-11-28 | Fujisawa Pharmaceut Co Ltd | Ophthalmic solution |
| US6069135A (en) * | 1989-09-21 | 2000-05-30 | Hyal Pharmaceutical Corporation | Use of hyaluronic acid or its derivatives to enhance delivery of therapeutic agents |
| US6194392B1 (en) | 1989-09-21 | 2001-02-27 | Hyal Pharmaceutical Corporation | Treatment of conditions and disease |
| US5985850A (en) * | 1989-09-21 | 1999-11-16 | Hyal Pharmaceuticals Corporation | Compositions comprising hyaluronic acid and drugs |
| US6048844A (en) * | 1989-09-21 | 2000-04-11 | Hyal Pharmaceutical Corporation | Treatment of conditions and disease |
| US5914314A (en) * | 1989-09-21 | 1999-06-22 | Hyal Pharmaceutical Corporation | Use of a form of hyaluronic acid and a medicinal agent for reducing rejection of organs transplantation in mammals |
| US5852002A (en) * | 1989-09-21 | 1998-12-22 | Hyal Pharmaceutical Corporation | Treatment of conditions and disease |
| US5830882A (en) * | 1989-09-21 | 1998-11-03 | Hyal Pharmaceutical Corporation | Compositions containing a form of hyaluronic acid and a medicinal agent for treating acne in mammals and methods for administration of such composition |
| US5811410A (en) * | 1989-09-21 | 1998-09-22 | Hyal Pharmaceutical Corporation | Method of administering of a hyaluronic acid and an NSAID to decrease side effects of the NSAID |
| US5929048A (en) * | 1989-09-21 | 1999-07-27 | Hyal Pharmaceutical Corporation | Treatment of conditions and disease |
| US5932560A (en) * | 1989-09-21 | 1999-08-03 | Hyal Pharmaceutical Corporation | Treatment of conditions and disease |
| US5985851A (en) * | 1989-09-21 | 1999-11-16 | Hyal Pharmaceutical Corporation | Use of hyaluronic acid or its derivatives in peritoneal dialysis and formulations thereof |
| US5614506A (en) * | 1991-07-03 | 1997-03-25 | Hyal Pharmaceutical Corporation | Use of hyaluronic acid and forms to prevent arterial restenosis |
| US6022866A (en) * | 1991-07-03 | 2000-02-08 | Hyal Pharmaceutical Corporation | Use of hyaluronic acid and forms to prevent arterial restenosis |
| US5990095A (en) * | 1991-07-03 | 1999-11-23 | Hyal Pharmaceutical Corporation | Use of hyaluronic acid and forms to prevent arterial restenosis |
| US5817644A (en) * | 1991-07-03 | 1998-10-06 | Hyal Pharmaceutical Corporation | Targeting of dosages of medicine and therapeutic agents |
| US6147059A (en) * | 1992-02-20 | 2000-11-14 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
| US5942498A (en) * | 1992-02-20 | 1999-08-24 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
| EP0735895A4 (en) * | 1993-11-19 | 2001-03-28 | Univ Sydney | A method for preventing or controlling cataract |
| EP0735895A1 (en) * | 1993-11-19 | 1996-10-09 | The University Of Sydney | A method for preventing or controlling cataract |
| GR970100233A (en) * | 1997-06-09 | 1999-02-26 | Use of organic, anti-oxidant substances for the protection of the lungs, the skin and the eyes from free radicals | |
| WO2001006868A1 (en) * | 1999-07-28 | 2001-02-01 | Biomar Group | Feed for salmonids |
| WO2008050776A1 (en) | 2006-10-26 | 2008-05-02 | Senju Pharmaceutical Co., Ltd. | Ophthalmic aqeous liquid preparation |
| JP2010180206A (en) * | 2009-01-09 | 2010-08-19 | Rohto Pharmaceut Co Ltd | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
| JP2016169240A (en) * | 2009-01-09 | 2016-09-23 | ロート製薬株式会社 | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
| JP2011030455A (en) * | 2009-07-30 | 2011-02-17 | Uha Mikakuto Co Ltd | Food material containing tryptophan-hyaluronic acid and food material containing peptide with high tryptophan-content and hyaluronic acid and methods for producing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6410500B2 (en) | 1989-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5955436A (en) | Use of platelet derived growth factor to enhance wound healing | |
| JPS61233622A (en) | Eye lotion composition | |
| EA002004B1 (en) | Composition for use in ophthalmologic surgeries (variants) and method therefor | |
| DE10161149B4 (en) | Use of heparin-containing ophthalmic agent | |
| CN107496439B (en) | Chitosan derivative-based disinfectant and preparation method thereof | |
| JP2001500860A (en) | Pharmaceutical composition having antimicrobial activity | |
| US7820639B2 (en) | Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same | |
| MXPA03011613A (en) | Ophthalmic composition containing n-acetylcysteine for the treat ment of dry-eye syndrome. | |
| Smolin et al. | Tretinoin and corneal epithelial wound healing | |
| US4444787A (en) | Ophthalmic topical use of collagen cross-linking inhibitors | |
| EP1121929B1 (en) | Composition comprising di- and trisodiumsalts of echinochrome for treating ocular conditions | |
| WO2010031096A1 (en) | Antimicrobially and antivirally acting composition | |
| RU2201213C1 (en) | Ophthalmic drop "karnosin" | |
| DE10360425A1 (en) | Compositions containing hyaluronic acid or its derivatives as sole active agent, useful for topical treatment of ophthalmological or rhinological allergic complications | |
| RU2128975C1 (en) | Ophthalmic drops "balarpan" | |
| CN100362991C (en) | Medicine composition for ophthalmology department | |
| MIDDLETON | SELENIUM BURN OF THE EYE: Report of a Case, with Review of the Literature | |
| Marquardt | Therapy of dry eye | |
| CN1965854A (en) | Moisturizing eye drop and preparation process therof | |
| RU2076671C1 (en) | Solution for protection and treatment of cornea sickness and damage | |
| RU2134559C1 (en) | Eye drops "cornealon" | |
| de Rötth | Local Action of Oils Containing Vitamin A: Experimental Contribution | |
| Speaker | Report from Sarasota: ARVO 1989 | |
| RU2180825C2 (en) | Method for treating corneal trauma under experimental conditions | |
| KR20220131021A (en) | Composition for treating conjunctivitis containing membrane free stem cell extract and a eye drop thereby |